Natural epigenetic processes precisely orchestrate the intricate gene network by expressing and suppressing genes at the right place and time, thereby playing an essential role in maintaining the cellular homeostasis. Environment-mediated alteration of this natural epigenomic pattern causes abnormal cell behavior and shifts the cell from the normal to a diseased state, leading to certain cancers and neurodegenerative disorders. Unlike heritable diseases that are caused by the irreversible mutations in DNA, epigenetic errors can be reversed. Inheritance of epigenetic memory is also a major concern in the clinical translation of the Nobel Prize-winning discovery of induced pluripotent stem cell technology. Consequently, there is an increasing interest in the development of novel epigenetic switch-based therapeutic strategies that could potentially restore the heritable changes in epigenetically inherited disorders. Here we give a comprehensive overview of epigenetic inheritance and suggest the prospects of therapeutic gene modulation using epigenetic-based drugs, in particular histone deacetylase inhibitors. This review suggests that there is a need to develop therapeutic strategies that effectively mimic the natural environment and include the ways to modulate the gene expression at both the genetic and epigenetic levels. The development of tailor-made small molecules that could epigenetically alter DNA in a sequence-specific manner is a promising approach for restoring defects in an altered epigenome and may offer a sustainable solution to some unresolved clinical issues.
References
[1]
Gordon, J.E. The New Science of Strong Materials, or Why You Don’t Fall through the Floor, 2nd ed.; Pelican-Penguin: London, UK, 1976; pp. 17–33.
[2]
Sapp, J. Genesis: the Evolution of Biology; Oxford University Press: Oxford, U.K, 2003; pp. 5–10.
[3]
Lamb, M.J.; Jablonka, E. Evolution in Four Dimensions: Genetic, Epigenetic, Behavioral, and Symbolic Variation in the History of Life; MIT Press: Cambridge, MA, USA, 2005; pp. 5–34.
[4]
Bhushan, B. Biomimetics-lessons from nature: an overview. Phil. Trans. R. Soc. A. 2009, 367, 1445–1486, doi:10.1098/rsta.2009.0011.
[5]
Bird, A. Perceptions of epigenetics. Nature 2007, 447, 396–398.
[6]
Frances, M.B.; Mukund, T.; Satyajit, M. Evolutionary cell biology: Lessons from diversity. Nat. Cell Biol. 2012, 14, 651, doi:10.1038/ncb2539.
[7]
Muneoka, K.; Allan, C.H.; Yang, X.; Lee, J.; Han, M. Mammalian regeneration and regenerative medicine. Birth Defects Research. Part C. Embryo Today 2008, 84, 265–280.
[8]
Riggs, A.D.; Russo, V.E.A.; Martienssen, R.A. Epigenetic mechanisms of gene regulation; Cold Spring Harbor Laboratory Press: Plainview, NY, USA, 1996; pp. 231–267.
[9]
Baltimore, D. Our genome unveiled. Nature 2001, 409, 814–816, doi:10.1038/35057267.
[10]
Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. Nature 2000, 403, 41–45.
[11]
Stein, G.S.; Zaidi, S.K.; Stein, J.L.; Lian, J.B.; van Wijnen, A.J.; Montecino, M.; Young, D.W.; Javed, A.; Pratap, J.; Choi, J.Y.; et al. Transcription-factor-mediated epigenetic control of cell fate and lineage commitment. Biochem. Cell Biol. 2009, 87, 1–6, doi:10.1139/O08-094.
[12]
Taverna, S.D.; Li, H.; Ruthenburg, A.J.; Allis, C.D.; Patel, D.J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 2007, 14, 1025–1040.
[13]
Jablonka, E.; Raz, G. Transgenerational epigenetic inheritance: prevalence, mechanisms, and implications for the study of heredity and evolution. Q. Rev. Biol. 2009, 84, 131–176, doi:10.1086/598822.
[14]
Garber, K. Breaking the silence: the rise of epigenetic therapy. J. Natl. Cancer Inst. 2002, 94, 874–875, doi:10.1093/jnci/94.12.874.
Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128, 693–705, doi:10.1016/j.cell.2007.02.005.
[17]
Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358, 1148–1159, doi:10.1056/NEJMra072067.
[18]
Chin, L.; Anderson, J.N.; Futreal, P.A. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 2011, 17, 297–303.
[19]
Yoo, C.B.; Jones, P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5, 37–50.
[20]
Waddington, C.H. The epigenotype. Endeavour 1942, 1, 18–20.
[21]
Rando, O.J.; Verstrepen, K.J. Timescales of genetic and epigenetic inheritance. Cell 2007, 128, 655–668, doi:10.1016/j.cell.2007.01.023.
[22]
Jablonka, E.; Lamb, M.J. Epigenetic Inheritance and Evolution: The Lamarckian Dimension; Oxford University Press: Oxford, U.K, 1995; pp. 133–160.
[23]
Canli, T. Genomic psychology: an emerging paradigm. EMBO Rep. 2007, 8, S30–S34, doi:10.1038/sj.embor.7400938.
[24]
Huxley, J. Epigenetics. Nature 1956, 177, 807.
[25]
Hattman, S. DNA methylation of T-even bacteriophages and of their nonglucosylated mutants: Its role in P1-directed restriction. Virology 1970, 42, 359–367, doi:10.1016/0042-6822(70)90279-5.
[26]
Waterland, R.A.; Jirtle, R.L. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol. Cell. Biol. 2003, 23, 5293–5300, doi:10.1128/MCB.23.15.5293-5300.2003.
Arai, J.; Li, S.; Hartley, D.M.; Feig, L.A. Transgenerational rescue of a genetic defect in long-term potentiation and memory formation by juvenile enrichment. J. Neuroscience 2009, 29, 1496–1502, doi:10.1523/JNEUROSCI.5057-08.2009.
[29]
Sollars, V.; Lu, X.; Xiao, L.; Wang, X.; Garfinkel, M.D.; Ruden, D.M. Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution. Nat. Genet. 2003, 33, 70–74.
[30]
Jablonka, E.; Lamb, M.J. Soft inheritance: challenging the modern synthesis. Genet. Mol. Biol. 2008, 31, 389–395, doi:10.1590/S1415-47572008000300001.
Henikoff, S.; Smith, M. Histone variants and epigenetics. Allis, D.C., Jenuwein, T., Reinberg, D., Caparros, M.L., Eds.; Epigenetics. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2007; pp. 249–264.
[33]
Jiang, Y.H.; Bressler, J.; Beaudet, A.L. Epigenetics and human disease. Annu. Rev. Genomics Hum. Genet. 2004, 5, 479–510, doi:10.1146/annurev.genom.5.061903.180014.
[34]
Pembrey, M.E.; Bygren, L.O.; Kaati, G.; Edvinsson, S.; Northstone, K.; Sjostrom, M.; Golding, J. Sex-specific, male-line transgenerational responses in humans. Eur. J. Hum. Genet. 2006, 14, 159–166.
[35]
Lumey, L.H.; Stein, A.D. Offspring birth weights after maternal intrauterine undernutrition: a comparison within sibships. Am. J. Epidemiol. 1997, 146, 810–819, doi:10.1093/oxfordjournals.aje.a009198.
[36]
Stein, A.D.; Lumey, L.H. The relationship between maternal and offspring birth weights after maternal prenatal famine exposure: the Dutch Famine Birth Cohort Study. Hum. Biol. 2000, 72, 641–654.
[37]
Kaati, G.; Bygren, L.O.; Pembrey, M.; Sjostrom, M. Transgenerational response to nutrition, early life circumstances and longevity. Eur. J. Hum. Genet. 2007, 15, 784–790, doi:10.1038/sj.ejhg.5201832.
[38]
Galler, J.R.; Seelig, C. Home-orienting behavior in rat pups: the effect of 2 and 3 generations of rehabilitation following intergenerational malnutrition. Dev. Psychobiol. 1981, 14, 541–548, doi:10.1002/dev.420140607.
[39]
Carone, B.R.; Fauquier, L.; Habib, N.; Shea, J.M.; Hart, C.E.; Li, R. Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals. Cell 2010, 143, 1084–1096, doi:10.1016/j.cell.2010.12.008.
[40]
Champagne, F.A. Epigenetic mechanisms and the transgenerational effects of maternal care. Front Neuroendocrinol. 2008, 29, 386–397, doi:10.1016/j.yfrne.2008.03.003.
[41]
Weaver, I.C. Epigenetic programming by maternal behavior and pharmacological intervention. Nature versus nurture: let’s call the whole thing off. Epigenetics 2007, 2, 22–28, doi:10.4161/epi.2.1.3881.
Polo, S.E.; Almouzni, G. Histone metabolic pathways and chromatin assembly factors as proliferation markers. Cancer Lett. 2005, 220, 1–9, doi:10.1016/j.canlet.2004.08.024.
[46]
Vidanes, G.M.; Bonilla, C.Y.; Toczyski, D.P. Complicated tails: histone modifications and the DNA damage response. Cell 2005, 121, 973–976, doi:10.1016/j.cell.2005.06.013.
[47]
Weinreich, M.; Palacios DeBeer, M.A.; Fox, C.A. The activities of eukaryotic replication origins in chromatin. Biochim. Biophys. Acta 2004, 1677, 142–157, doi:10.1016/j.bbaexp.2003.11.015.
[48]
Zhang, J.; Xu, F.; Hashimshony, T.; Keshet, I.; Cedar, H. Establishment of transcriptional competence in early and late S phase. Nature 2002, 420, 198–202.
[49]
Santos-Rosa, H.; Caldas, C. Chromatin modifier enzymes, the histone code and cancer. Eur. J. Cancer 2005, 41, 2381–2402, doi:10.1016/j.ejca.2005.08.010.
[50]
Feinberg, A.P.; Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301, 89–92.
[51]
Minucci, S.; Nervi, C.; Lo Coco, F.; Pelicci, P.G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 2001, 20, 3110–3115, doi:10.1038/sj.onc.1204336.
[52]
He, L.Z.; Tolentino, T.; Grayson, P.; Zhong, S.; Warrell, R.P., Jr.; Rifkind, R.A.; Marks, P.A.; Richon, V.M.; Pandolfi, P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 2001, 108, 1321–1330.
[53]
Bereshchenko, O.R.; Gu, W.; Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nature Genet. 2002, 32, 606–613.
[54]
Kumar, R.; Wang, R.A.; Bagheri-Yarmand, R. Emerging roles of MTA family members in human cancers. Semin. Oncol. 2003, 30, 30–37.
[55]
Toh, Y.; Ohga, T.; Endo, K.; Adachi, E.; Kusumoto, H.; Haraguchi, M.; Okamura, T.; Nicolson, G.L. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int. J. Cancer 2004, 110, 362–367, doi:10.1002/ijc.20154.
[56]
Fraga, M.F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 2005, 37, 391–400.
[57]
Florean, C.; Schnekenburger, M.; Grandjenette, C.; Dicato, M.; Diederich, M. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 2011, 3, 581–609, doi:10.2217/epi.11.73.
[58]
Tai, K.Y.; Shiah, S.G.; Shieh, Y.S.; Kao, Y.R.; Chi, C.Y.; Huang, E.; Lee, H.S.; Chang, L.C.; Yang, P.C.; Wu, C.W. DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene 2007, 26, 3989–3997.
[59]
Musolino, C.; Sant'antonio, E.; Penna, G.; Alonci, A.; Russo, S.; Granata, A. Epigenetic therapy in myelodysplastic syndromes. Eur. J. Haematol. 2010, 84, 463–473, doi:10.1111/j.1600-0609.2010.01433.x.
[60]
Minucci, P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6, 38–51, doi:10.1038/nrc1779.
[61]
Butler, L.M.; Zhou, X.; Xu, W.S.; Scher, H.I.; Rifkind, R.A.; Marks, P.A. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA 2002, 99, 11700–11705.
[62]
Garcia-Manero, G.; Tambaro, F.P.; Bekele, N.B.; Yang, H.; Ravandi, F.; Jabbour, E.; Borthakur, G.; Kadia, T.M.; Konopleva, M.Y.; Faderl, S.; et al. Phase II Trial of Vorinostat with Idarubicin and Cytarabine for patients with newly diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J. Clin. Oncol. 2012, 30, 2204–2210.
[63]
Katherine, V.; Tom, C.K. Overview of the Classical Histone Deacetylase Enzymes and Histone Deacetylase Inhibitors. ISRN Cell Biol. 2012, Article ID 130360, doi:10.5402/2012/130360.
[64]
Gore, S.D. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 2002, 8, 963–970.
[65]
Raffoux, E.; Chaibi, P.; Dombret, H.; Degos, L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica. 2005, 90, 986–988.
[66]
Cuneo, K.C.; Fu, A.; Osusky, K.; Huamani, J.; Hallahan, D.E.; Geng, L. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs 2007, 18, 793–800, doi:10.1097/CAD.0b013e3280b10d57.
[67]
Qian, X.; LaRochelle, W.J.; Ara, G.; Wu, F.; Petersen, K.D.; Thougaard, A.; Sehested, M.; Lichenstein, H.S.; Jeffers, M. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol. Cancer. Ther. 2006, 8, 2086–2095.
[68]
Ryan, Q.C. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005, 23, 3912–3922, doi:10.1200/JCO.2005.02.188.
[69]
Chen, L.; Kasai, T.; Li, Y.; Sugii, Y.; Jin, G.; Okada, M.; Vaidyanath, A.; Mizutani, A.; Satoh, A.; Kudoh, T.; et al. A model of cancer stem cells derived from mouse induced pluripotent stem cells. PLoS One 2012, 7, e33544.
[70]
Poss, K.D. Advances in understanding tissue regenerative capacity and mechanisms in animals. Nature Rev. Genet. 2010, 11, 710–722, doi:10.1038/nrg2879.
[71]
Brockes, J.P.; Kumar, A. Plasticity and reprogramming of differentiated cells in amphibian regeneration. Nature Rev. Mol. Cell Biol. 2002, 3, 566–574, doi:10.1038/nrm881.
[72]
Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2007, 126, 663–676, doi:10.1016/j.cell.2006.07.024.
[73]
Christen, B.; Robles, V.; Raya, M.; Paramonov, I.; Belmonte, J.C. Regeneration and reprogramming compared. BMC Biol. 2010, 8, 5, doi:10.1186/1741-7007-8-5.
[74]
Hochedlinger, K.; Plath, K. Epigenetic reprogramming and induced pluripotency. Development 2009, 136, 509–523, doi:10.1242/dev.020867.
[75]
Huangfu, D.; Osafune, K.; Maehr, R.; Guo, W.; Eijkelenboom, A.; Chen, S.; Muhlestein, W.; Melton, D.A. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol. 2008, 26, 1269–1275, doi:10.1038/nbt.1502.
[76]
Mali, P.; Chou, B.K.; Yen, J.; Ye, Z.; Zou, J.; Dowey, S.; Brodsky, R.A.; Ohm, J.E.; Yu, W.; Baylin, S.B.; et al. Butyrate Greatly Enhances Derivation of Human Induced Pluripotent Stem Cells by Promoting Epigenetic Remodeling and the Expression of Pluripotency-Associated Genes. Stem Cells 2010, 28, 713–720, doi:10.1002/stem.402.
[77]
Chen, H.P.; Denicola, M.; Qin, X. HDAC inhibition promotes cardiogenesis and the survival of embryonic stem cells through proteasome-dependent pathway. J. Cellular Biochem. 2011, 112, 3246–3255, doi:10.1002/jcb.23251.
[78]
Balasubramaniyan, V.; Boddeke, E.; Bakels, R. Effects of histone deacetylation inhibition on neuronal differentiation of embryonic mouse neural stem cells. Neuroscience 2006, 143, 939–951, doi:10.1016/j.neuroscience.2006.08.082.
[79]
Brons, I.G.M.; Smithers, L.E.; Trotter, M.W.B. Derivation of pluripotent epiblast stem cells from mammalian embryos. Nature 2007, 448, 191–195.
[80]
Schneider, J.W.; Gao, Z.; Li, S. Small-molecule activation of neuronal cell fate. Nature Chem. Biol. 2008, 4, 408–410, doi:10.1038/nchembio.95.
Hao, Y.; Creson, T.; Zhang, L.; Li, P.; Du, F.; Yuan, P.; Gould, T.D.; Manji, H.K.; Chen, G. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 2004, 24, 6590–6599, doi:10.1523/JNEUROSCI.5747-03.2004.
[83]
Rossler, R.; Boddeke, E.; Copray, S. Differentiation of non-mesencephalic neural stem cells towards dopaminergic neurons. Neuroscience 2010, 170, 417–428, doi:10.1016/j.neuroscience.2010.07.023.
[84]
Dai, X.; Hao, J.; Hou, X.J. Somatic nucleus reprogramming is significantly improved by m-carboxycinnamic acid bishydroxamide, a histone deacetylase inhibitor. J. Biol. Chem. 2010, 285, 31002–31010, doi:10.1074/jbc.M110.136085.
[85]
Lister, R.; Pelizzola, M.; Kida, Y.S.; Hawkins, D.; Nery, J.R.; Hon, G.; Antosiewicz-Bourget, J.; O`Malley, R.; Castanon, R.; Klugman, S.; et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471, 68–73.
[86]
Onder, T.T.; Kara, N.; Cherry, A.; Sinha, A.U.; Zhu, N.; Bernt, K.M.; Cahan, P.; Marcarci, B.O.; Unternaehrer, J.; Gupta, P.B.; et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 2012, 483, 598–602.
[87]
Pandian, G.N.; Sugiyama, H. Programmable genetic switches to control transcriptional machinery of pluripotency. Biotechnol. J. 2012, 7, 798–809.
[88]
Cloud, J. Why your DNA isn’t your destiny. Time Magazine 2010, 61, 175.
[89]
You, J.S.; Jones, P.A. Cancer genetics and epigenetics: Two sides of the same coin? Cancer cell 2012, 22, 9–20, doi:10.1016/j.ccr.2012.06.008.
[90]
Kashiwazaki, G.; Bando, T.; Yoshidome, T.; Masui, S.; Takagaki, T.; Hashiya, K.; Pandian, G.N.; Yasuoka, J.; Akiyoshi, K.; Sugiyama, H. Synthesis and biological properties of highly sequence-specific-alkylating N-Methylpyrrole-N-Methylimidazole polyamide conjugates. J. Med. Chem. 2012, 55, 2057–2066.
[91]
Shinohara, K.; Bando, T.; Sasaki, S.; Sakakibara, Y.; Minoshima, M.; Sugiyama, H. Antitumor activity of sequence-specific alkylating agents: Pyrrole-imidazole CBI conjugates with indole linker. Cancer Sci. 2006, 97, 219–225, doi:10.1111/j.1349-7006.2006.00158.x.
[92]
Ohtsuki, A.; Kimura, M.T.; Minoshima, M.; Suzuki, T.; Ikeda, M.; Bando, T.; Nagase, H.; Shinohara, K.; Sugiyama, H. Synthesis and properties of PI polyamide-SAHA conjugate. Tetrahedron Lett. 2009, 50, 7288–7292, doi:10.1016/j.tetlet.2009.10.034.
[93]
Pandian, G.N.; Shinohara, K.; Ohtsuki, A.; Nakano, Y.; Masafumi, M.; Bando, T.; Nagase, H.; Yamada, Y.; Watanabe, A.; Terada, N.; et al. Synthetic small molecules for epigenetic activation of pluripotent genes in mouse embryonic fibroblasts. ChemBioChem 2011, 12, 2822–2828, doi:10.1002/cbic.201100597.
[94]
Pandian, G.N.; Ohtsuki, A.; Bando, T.; Sato, S.; Hashiya, K.; Sugiyama, H. Development of programmable small DNA-binding molecules with epigenetic activity for induction of core pluripotency genes. Bioorg. Med. Chem. 2012, 20, 2656–2660, doi:10.1016/j.bmc.2012.02.032.
[95]
Pandian, G.N.; Nakano, Y.; Sato, S.; Morinaga, H.; Bando, T.; Nagase, H.; Sugiyama, H. A synthetic small molecule for rapid induction of multiple pluripotency genes in mouse embryonic fibroblasts. Sci. Rep. 2012, 2, e544.
[96]
Li, R.; Liang, J.; Ni, S.; Zhou, T.; Qing, X.; Li, H.; He, W.; Chen, J.; Li, F.; Zhuang, Q. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010, 7, 51–63, doi:10.1016/j.stem.2010.04.014.
[97]
Matsui, T.; Takano, M.; Yoshida, K.; Ono, S.; Fujisaki, C.; Matsuzaki, Y.; Toyama, Y.; Nakamura, M.; Okano, H.; Akamatsu, W. Neural stem cells directly differentiated from partially reprogrammed fibroblasts rapidly acquire gliogenic competency. Stem Cells 2012, doi:10.1002/stem.1091.
[98]
Lister, R.; Gregory, B.D.; Ecker, J.R. Next is now: new technologies for sequencing of genomes, transcriptomes, and beyond. Curr. Opin. Plant. Biol. 2009, 12, 107–118, doi:10.1016/j.pbi.2008.11.004.
[99]
Godfrey, K.M.; Gluckman, P.D.; Hanson, M.A. Developmental origins of metabolic disease: life course and intergenerational perspectives. Trends Endocrinol. Metabol. 2010, 21, 199–205, doi:10.1016/j.tem.2009.12.008.
Franklin, T.B.; Mansuy, I.M. Epigenetic inheritance in mammals: evidence for the impact of adverse environmental effects. Neurobiol. Dis. 2010, 39, 61–65, doi:10.1016/j.nbd.2009.11.012.
[102]
Meaney, M.J. Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Annu. Rev. Neurosci. 2001, 24, 1161–1192, doi:10.1146/annurev.neuro.24.1.1161.
[103]
McGowan, P.O.; Sasaki, A.; D’Alessio, A.C.; Dymov, S.; Labonte, B.; Szyf, M. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 2009, 12, 342–348.
[104]
Rodriguez-Paredes, M.; Esteller, M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17, 330–339, doi:10.1038/nm.2305.
[105]
Hamm, C.A.; Costa, F.F. The impact of epigenomics on future drug design and new therapies. Drug Discov. Today 2011, 16, 626–635, doi:10.1016/j.drudis.2011.04.007.
Harper, L.V. Epigenetic inheritance and the intergenerational transfer of experience. Psychol. Bull. 2005, 131, 340–360, doi:10.1037/0033-2909.131.3.340.
[108]
Daxinger, L.; Whitelaw, E. Understanding transgenerational epigenetic inheritance via the gametes in mammals. Nat. Rev. Genet. 2012, 13, 153–162.
[109]
Minoshima, M.; Bando, T.; Sasaki, S.; Fujimoto, J.; Sugiyama, H. Pyrrole-Imidazole hairpin polyamides with high affinity at 5'-CGCG-3' DNA sequence; Influence of cytosine methylation on binding. Nucleic Acids Res. 2008, 36, 2889–2894, doi:10.1093/nar/gkn116.
[110]
Vaijayanthi, T.; Bando, T.; Pandian, G. N.; Sugiyama, H. Progress and prospects of pyrrole-imidazole polyamide-fluorophore conjugates as sequence-selective DNA probes. ChemBioChem 2012, 13, 2170–2185, doi:10.1002/cbic.201200451.
[111]
Petronis, A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature 2010, 465, 721–727.
[112]
Feinberg, A.P. Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447, 433–440.
[113]
Bohacek, J.; Mansuy, I.M. Epigenetic inheritance of disease and disease risk. Neuropsychopharmacol. Rev. 2012, 1–17.
